13087 Results

People

  1. Giralt
    Giralt
  2. Perales
    Perales
  3. Levine
    Levine
  4. Zelenetz
    Zelenetz
  5. Horwitz
    Horwitz
  6. Abdel-Wahab
    Abdel-Wahab
  7. Scheinberg
    Scheinberg
  8. Jakubowski
    Jakubowski
  9. Landau
    Landau
  10. Shah
    Shah

Groups

  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)
  7. Lymphoma (2639)
  8. Sloan Kettering Institute Faculty (2602)
  9. Executive Committee, Center for Hematologic Malignancies (2358)
  10. Survivorship Research (2328)
  1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic significance of genomic alterations in mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Yang, W.; Bantilan, K. S.; Berger, M.; Schultz, N.; Batlevi, C.; Zelenetz, A. D.
    Blood (2016)

    Fulltext@MSK | Save
  • Whole exome sequencing from nine independent sites of extraosseous disease in a single patient with relapsed multiple myeloma show that extramedullary disease arise through a combination of branched and parallel evolution
    Meeting Abstract

    Landau, H.; Fan, J.; Giralt, S. A.; Peled, J. U.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Korde, N. S.; Mailankody, S.; Chung, D. J.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Treatment-related infections and risk factors in patients with myeloproliferative neoplasms treated with ruxolitinib
    Meeting Abstract

    King, A. C.; Hsu, M.; Mauro, M. J.; Rampal, R. K.
    Blood (2016)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) followed by 2 years of lenalidomide maintenance (CRd-R): Updated results of a phase 2 study
    Meeting Abstract

    Kazandjian, D.; Korde, N. S.; Roschewski, M.; Mailankody, S.; Morrison, C.; Manasanch, E. E.; Kwok, M. L.; Tageja, N.; Bhutani, M.; Zingone, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Longitudinal (18)f-FDG-PET-CT analysis in newly diagnosed multiple myeloma (NDMM) patients following carfilzomib, lenalidomide, dexamethasone induction and lenalidomide maintenance (CRd-R)
    Meeting Abstract

    Korde, N. S.; Kazandjian, D.; Roschewski, M.; Mailankody, S.; Hultcrantz, M.; Yuan, C. M.; Stetler-Stevenson, M.; Choyke, P.; Hassoun, H.; Lesokhin, A. M.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • The impact of prior malignancies on second malignancies and survival in MM patients: A population-based study
    Meeting Abstract

    Jonsdottir, G.; Lund, S. H.; Björkholm, M.; Turesson, I.; Wahlin, A.; Hultcrantz, M.; Porwit, A.; Landgren, O.; Kristinsson, S. Y.
    Blood (2016)

    Fulltext@MSK | Save
  • The final report of a phase I/II study of panobinostat in combination with ICE (ifosfamide, carboplatin and etoposide) in patients (pts) with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL)
    Meeting Abstract

    Hu, B.; Younes, A.; Claret, L.; Feng, L.; Westin, J. R.; Fowler, N.; Neelapu, S.; Hagemeister, F. B.; Rodriguez, M. A.; Samaniego, F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Real-world clinical and economic burden of hematopoietic cell transplantation among a large US commercially insured populationhematopoietic cell transplantation among a large US commercially insured population
    Meeting Abstract

    Josephson, N. C.; Garfin, P. M.; Richhariya, A.; Bonafede, M.; Donna, M.; Cai, Q.; Perales, M.
    Blood (2016)

    Fulltext@MSK | Save
  • Long-term follow-up of the efficacy and safety of ponatinib in Philadelphia chromosome-positive leukemia patients with the T315I mutation
    Meeting Abstract

    Jabbour, E. J.; Cortes, J. E.; Talpaz, M.; Baccarani, M.; Mauro, M. J.; Hochhaus, A.; Hughes, T. P.; Guilhot, F.; Deininger, M. W.; Shah, N.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Sustained high rates of complete response and minimal residual disease negativity after 8 cycles of carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) followed by 2 years of lenalidomide maintenance (CRd-R) in patients with high-risk smoldering multiple myeloma: Updated results of clinical and correlative phase 2 study
    Meeting Abstract

    Kazandjian, D.; Korde, N. S.; Roschewski, M.; Mailankody, S.; Morrison, C.; Manasanch, E. E.; Kwok, M. L.; Tageja, N.; Bhutani, M.; Zingone, A.; more...
    Blood (2016)

    Fulltext@MSK | Save